BUD vs TCRX
BUD (BUD) versus Tscan Therapeutics Inc (TCRX) — a side-by-side from cached financials, not a winner call.
BUD (BUD) common stock.
Tscan Therapeutics Inc (TCRX) is a biotechnology company listed on NASDAQ.
BUD does not have a complete income-statement cache yet.
Latest reported TCRX revenue for 2026-06-30 was $2.0M. Net income was -$59.0M. TCRX currently screens at market cap $62.1M.
BUD currently screens at market cap $0. TCRX currently screens at market cap $62.1M.
Not investment advice. Open the BUD and TCRX stock pages for the full models.
Not investment advice.